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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
photodynamic therapy improves the survival rate of patients with unresectable
cholangiocarcinoma.
Study Design: Systematic review of two randomized controlled trials and one
retrospective cohort study published in 2014, 2014, and 2016.
Data Sources: Two randomized controlled trials and one retrospective cohort study
examining photodynamic therapy in patients with unresectable cholangiocarcinoma. Data
sources were found using PubMed and EBSCOhost.
Outcome(s) Measured: Overall survival and progression free survival were measured in
patients who underwent photodynamic therapy for unresectable cholangiocarcinoma.
Each study analyzed overall survival using a Kaplan-Meier survival curve.
Results: The RCT by Hauge et al. found photodynamic therapy to improve overall
survival rate in patients with unresectable cholangiocarcinoma compared to patients who
did not receive photodynamic therapy. The RCT by Park et al. found photodynamic
therapy plus oral flouropyrimidine to improve overall survival over photodynamic
therapy alone. The retrospective cohort study by Strand et al. was found to show no
significant difference in overall survival with patients who underwent ERCP-directed
radiofrequency ablation versus ERCP-directed photodynamic therapy.
Conclusions: There is conflicting evidence as to whether photodynamic therapy
improves the survival rate of patients with unresectable cholangiocarcinoma. Further
Key Words: Photodynamic therapy, cholangiocarcinoma, overall survival
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INTRODUCTION
Cholangiocarcinoma is a rare and debilitating cancer of the biliary tract. The
majority of cholangiocarcinoma cases are not detected until metastasis has occurred and
there is no chance of cure through medical intervention. The prognosis of a patient with
cholangiocarcinoma is not good even with early detection and traditional treatment that
includes chemotherapy and radiation. This systematic review evaluates two randomized
controlled trials (RCT) and one retrospective cohort study comparing the efficacy of
photodynamic therapy with traditional treatment methods for unresectable
cholangiocarcinoma to traditional treatment methods such as chemotherapy and radiation.
Cholangiocarcinoma is a rare cancer that is increasing in incidence every year.
This aggressive malignancy has about 5,000 newly diagnosed cases each year.1 The
incidence of cholangiocarcinoma is very high in Southeast Asia, but the number of cases
are steadily increasing in the United States. A patient diagnosed with
cholangiocarcinoma warrants the highest oncologic care available. High-level care
comes with a high-level price in hospital equipment, utilities, staff, and medicine. The
number of hospital admissions for patients with cholangiocarcinoma was 11,970.2 The
average length of stay of hospital admissions in 2012 was 7.9 days.2 The majority, if not
all, of the patient hospital admissions require nurses, physicians, unit clerks, hospital
rooms, equipment, utilities, and medications which can make each stay exceptionally
expensive. In 2012, the average cost for a cholangiocarcinoma patient’s hospital charges
was $77,753.2
The most common location for cholangiocarcinoma is the perihilar region of the
biliary tract.1 The perihilar area of the biliary tract is the junction where the left hepatic
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duct and the right hepatic duct join together to form the common bile duct. Tumors in the
perihilar location of the biliary tract are known as Klatskin tumors.3 Most patients who
suffer from cholangiocarcinoma are over the age of 60 and more commonly males.2
Patients look to seek medial treatment typically for abdominal pain and/or jaundice of
skin and sclera of the eyes.2 Cholangiocarcinoma coincides with a multitude of
complications that severely inhibit the quality of life of a patient. These complications
include, but are not limited to, cachexia, cholestasis, cholangitis, biliary obstruction, and
hepatic dysfunction.1 Evaluation of the patient typically involves imaging studies that
show biliary mass on abdominal ultrasound followed by MRI or magnetic resonance
cholangiopancreatography (MRCP) and biopsy to diagnose if not confirmed on imaging.2
The gold standard of treatment for cholangiocarcinoma is surgical resection of the
disease.1 However, surgical resection is often not possible because the disease is often
detected too late for a patient to be a candidate for surgical resection due to metastasis or
risks outweighing the benefits of the surgery concerning the quality of life of the patient.
Other standard forms of treatment include biliary stents to alleviate obstruction of the
biliary tract. These stents include temporary plastic stents and self-expandable metal
stents.1 The stents are placed in the biliary tract via endoscopy or interventional radiology
which is minimally invasive to the patient.1 Typical standards of care for
cholangiocarcinoma include chemotherapy and radiation.1 Other adjuvant therapies
include transarterial chemoembolization, percutaneous transhepatic cholangiography
tubes, transarterial embolization, and liver transplantation.
The five-year survival rate of patients with cholangiocarcinoma is approximately
15%.3 Photodynamic therapy is an ablation therapy that uses localized photosensitization
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to make the targeted cells become necrotic or induce apoptosis.1 Research has shown
mixed results of photodynamic therapy improving survival rate of patients with
unresectable cholangiocarcinoma as isolated therapy. Research shows that endoscopic
retrograde cholangiopancreatography (ERCP) with photodynamic therapy is associated
with improved survival rate compared to only biliary stent placement.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not
photodynamic therapy improves the survival rate of patients with unresectable
cholangiocarcinoma.
METHODS
Studies for this EBM were selected based on the population, intervention,
comparison, outcome, and type of study in each article. This EBM selected two
randomized controlled trials (RCT) and one retrospective cohort study that evaluated
patients between the ages of 35-79 with unresectable cholangiocarcinoma for median
progression free survival rate and one year survival rate. Interventions in the studies
included photodynamic therapy, ERCP directed photodynamic therapy, and
photodynamic therapy plus biliary stent plus Gemcitabine and Capacitabine (GemCap).
Comparison groups included Photodynamic therapy plus oral flouropyrimidine, ERCP
directed radiofrequency ablation, and biliary stent plus GemCap.
Data sources were articles found using searches through PubMed and EBSCOhost
with keywords including “cholangiocarcinoma”, “photodynamic therapy”, and
“randomized controlled trial”. All articles selected were published in the English
language. Each article was published in a peer-reviewed journal. The author of this
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systematic review performed all of the research used in this paper. The articles were
selected based on their relevance to the clinical question, “Does photodynamic therapy
improve the survival rate of patients with unresectable cholangiocarcinoma?” The
inclusion criteria for this review was randomized controlled trial or retrospective cohort
study published after 2012 with patients with unresectable cholangiocarcinoma. This
review excluded patients who were under the age of 18 and patients who had resectable
cholangiocarcinoma. In order to determine the significance of the results published in the
articles, the numbers needed to treat (NNT), absolute benefit increase (ABI), relative
benefit increase (RBI), and p-values were calculated. One article had continuous data
that could not be statistically converted but was quantified I median number of days of
survival.3 One article had a p-value that was recorded, however, this article had
continuous data that could not be statistically converted and was calculated as median
number of months survived.1 One article had dichotomous data that listed a p-value.4
This article had data that was able to have calculations of numbers needed to treat,
absolute benefit increase, and relative benefit increase.
Table 1 – Demographics & Characteristics of included studies

Study

Type

Hauge3, RCT
2016

# Age
Pts (yrs)
20

3575

Inclusion
Criteria

Exclusion
Criteria

W/D

Unresectable
or recurrent/
metastatic
biliary tract
cancer with
no previous
chemo or
radiation
therapy, no

Evidence
of
ongoing
infection
and life
expectancy of <
3 months

5

Interventions

Stent,
temoporfin/
photodynamic
therapy,
GemCap
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additional
cancer within
last 5 years

Park4,
2014

RCT

51

Strand1, Retrospective 48
2014
Cohort Study

64 +
11

5579

Patients with
locally
advanced
unresectable
hilar
cholangiocarcinoma
with no prior
chemotherapy
or
radiotherapy,
no serious or
uncontrolled
medical
illness,
adequate
bone marrow
function
Patients over
18 years old
diagnosed
with
unresectable
cholangiocarcinoma

Porphyria
or
previous
placement
of biliary
metal
stent

8

Photodynamic
therapy

Patients
0
who were
capable of
having
surgical
resection
of
cholangiocarcinoma

ERCP directed
photodynamic
therapy

OUTCOMES MEASURED
The outcomes measured in all three studies were patient overall survival after
treatment with photodynamic therapy. Studies measured survival time from the day the
patient entered into the trial until the day of the patient’s death.1,3,4
In the article by Strand et al., the primary outcome measured was the overall
survival of patients in months. Total months were calculated starting from the time the
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patient received the intervention until patient death. Median survival of patients in the
intervention and comparison groups was analyzed using a Kaplan-Meier survival curve.1
In the article by Hauge et al., the outcomes measured were progression free
survival and overall survival. Both outcomes were calculated into median number of
days for both the intervention group and the comparison group. Ten patients were in
each group respectively. The data used to determine outcome measurements was started
on the day of initial randomization of the study until the day of patient death. Median
overall survival was analyzed using a Kaplan-Meier survival curve.3
In the article by Park et al., overall survival and progression free survival were
measured. The time of data calculation was from the date of randomization until the date
of patient death for overall survival. Progression free survival was measured from date of
randomization until date of death or disease progression. Overall survival and
progression free survival were analyzed using two separate Kaplan-Meier curves.4
RESULTS
This systematic review used two RCTs and one retrospective cohort study that
displayed both continuous and dichotomous data comparing photodynamic therapy
versus other treatment methods for unresectable cholangiocarcinoma that will be
discussed later in this review. Each study had inclusion and exclusion criteria for the
selection of patients, which can be found in Table 1.
In the retrospective cohort study by Strand et al., 48 patients with unresectable
cholangiocarcinoma agreed and gave consent to be included in this study that received
ERCP treatment between January 2008 and September 2012 at a tertiary-care academic
medical center.1 The patients were divided into two groups based on the type of treatment
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the patient received. The first group consisted of 16 patients who received ERCPdirected radiofrequency ablation.1 The second group consisted of 32 patients who
received ERCP-directed photodynamic therapy.1 At the time of statistical analysis, 4 out
of 16 patients (25%) were alive in the radiofrequency ablation group.1 The median
survival of this group was 9.6 months with a confidence interval of 95%.1 The range of
survival in the group was 5.1-11.7 months.1 At the same time, 0 out of 32 patients (0%)
were alive in the photodynamic therapy group.1 The median survival of the group was
7.5 months with a confidence interval of 95%.1 The range of survival in the group was
4.3-16 months.1 A Kaplan-Meier survival curve analyzed the survival rate of patients
who received ERCP-directed radiofrequency ablation and ERCP-directed photodynamic
therapy. The difference in overall survival between patients of either group was not
statistically significant with a p-value of 0.799 (see table 2).1 Strand et al also calculated
an adjusted survival rate for both groups based on factors of age, sex, distant metastasis,
time between diagnosis and initial treatment, and radiofrequency ablation using the Cox
proportional hazard model.1 The only variable of that showed a statistically significant
negative correlation with survival was distant metastasis with a p-value of 0.014.1
Table 2: Overall survival rate of ERCP-directed therapy1
Group
ERCP-directed
radiofrequency ablation
therapy
ERCP-directed
photodynamic therapy

Overall survival rate

P-value

9.6 months

0.799

7.5 months

0.799

In the RCT by Hauge et al., 20 patients with unresectable cholangiocarcinoma
agreed and gave consent to participate in the study that took place from June 2008-
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November 2011.3 The 20 patients were randomized into two groups, Arm A and Arm B.
Arm A consisted of 10 patients who were to receive photodynamic therapy plus a biliary
stent plus GemCap (Gemcitabine 1000 mg/m2 day 1 and day 8 and Capacitabine 650
mg/m2 two times a day days 1-14 every third week).3 During the study 3 patients in Arm
A were unable to receive GemCap due to progression of infection and only received
photodynamic therapy plus a biliary stent.3 Arm B consisted of 10 patients who were to
receive GemCap plus a biliary stent.3 During the study two patients withdrew from the
study and only received a biliary stent due to thrombocytopenia.3 Hauge et al. found that
Arm A had a median survival rate of 311 days for 7 patients who received photodynamic
therapy plus stent plus GemCap.3 The range of survival was 178-1060 days.3 Arm B had
a median survival rate of 336 days for 8 patients who received GemCap plus stent.3 The
range of survival was 110-690 days.3 Median progression free survival of the 7 Arm A
patients was 175 days with a range of 90-600 days.3 Arm B had a median progression
free survival of 96 days with a range of 56-422 days (see table 3).3 Hauge et al. created a
Kaplan-Meier survival curve to analyze the difference of median overall survival
between the two groups. There was no adverse effects to the therapy reported by Hauge
et al.3 Only 15 patients that were included in the study at time of data collection
completed the intended therapy without withdrawal or alteration in treatment.3 Statistical
values were in published in this RCT.
Table 3: Median overall survival in days3
Group
Arm A (Photodynamic
therapy+GemCap+Stent)
Arm B (GemCap+Stent)

Median Overall Survival
311 days
336 days
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In the RCT by Park et al., 43 patients with unresectable cholangiocarcinoma
agreed and gave consent to participate in the study that took place from February 2009 to
May 2012.4 The 43 patients were randomized into two groups. The first group, Group
A, had 21 patients and was given photodynamic therapy plus oral flouropyrimidine.4 The
second group, Group B, had 22 patients was given only photodynamic therapy.4 Park et
al. found that Group A patients had a one year survival rate of 76.2% compared to 32%
Group B patients who were given only photodynamic therapy.4 A log-rank test was used
to evaluate the results which were found to be statistically significant with a p-value of
0.003.4 The median overall survival of patients in group A was 17 months with a
confidence interval of 95%.4 Group B median overall survival was 8 months with a
confidence interval of 95%.4 This data was then analyzed on a Kaplan-Meier curve. A
log-rank test was used to evaluate the results which were found to be statistically
significant with a p-value of 0.005.4 Relative benefit increase (RBI) was calculated to be
-58% and absolute benefit increase (ABI) was calculated to be -44.2%. Numbers needed
to treat (NNT) was calculated to be -2, (see table 4) meaning that for every 2 patients
treated with photodynamic therapy, one less patient will survive one year after the time
treatment is started compared to control. There were no adverse effects in Group B. In
group A, 7 patients presented with toxicity (6 non-hematologic, 1 hematologic).4
Adverse events related to tumor progression in patients such as metastasis. At the
conclusion of the follow-up period of the study, 3 patients from Group A were alive and
1 patient from Group B.4 The overall survival rate of patients treated with photodynamic
therapy was significantly less than patients treated with photodynamic therapy plus oral
flouropyrimidine for unresectable cholangiocarcinoma.4
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Table 4: Analysis of treatment efficacy and statistical significance4
Study

CER

EER

RBI

ABI

NNT

P-value

Park

76.2%

32%

-58%

-44.2%

-2

0.003

DISCUSSION
Photodynamic therapy’s mechanism of action requires a photosensitizing agent,
such as temoporfin, that enters the patient intravenously.5 The photosensitizing agent is
then exposed to a light source calibrated to a specific wavelength of intensity depending
on the location of the target tissue.5 This light then creates oxygen with the
photosensitizing agent to create cellular apoptosis that ultimately leads to cell death.5
Cancer cells are more susceptible to the oxygen that is generated than normal cells.
Normal cells do not retain the photosensitizer as long as cancer cells which is why the
light therapy is administered 1-3 days after the patient is given the photosensitizer.5 The
light source of the therapy typically comes from a laser. Adverse effects of
photodynamic therapy include photosensitivity for up to six weeks after treatment,
scarring, burns, and pain to affected tissue.5 Photodynamic therapy is considered a
localized therapy that is contraindicated in cancers that have metastasized and cancers
that may have too much growth or large surface area.5 The main limitation of therapy is
that the target site must be close to the skin to be efficient due to the penetrating ability of
light through the skin.
The FDA does not currently approve photodynamic therapy for treatment of
cholangiocarcinoma as clinical trials are still evaluating the effectiveness of the therapy.5
The studies that were analyzed in this systematic review had limitations of small sample
sizes and different comparison groups to the intervention. Small sample sizes could be
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attributed to the small number of cases of unresectable cholangiocarcinoma. Other
limitations included complications from the cancer such as cholangitis, infection, and
biliary tract obstruction.1,3,4
CONCLUSION
There is conflicting evidence as to whether photodynamic therapy improves the
survival rate of patients with unresectable cholangiocarcinoma. The study by Strand et
al. reported no statistical significance between survival rates between ERCP-directed
radiofrequency ablation and ERCP-directed photodynamic therapy. The RCT by Hauge
et al. reported progression free survival rate to be greater in patients who received
photodynamic therapy. The RCT by Park et al. showed that patients who received
photodynamic therapy plus oral flouropyrimidine had better overall survival than patients
with photodynamic therapy.
Increased study size is suggested for future studies. None of the studies in this
review exceeded 50 patients that consented to participate. Patients in the studies analyzed
had various complications from cholangiocarcinoma that skewed the results of the study
and may have contributed to hasten death in patients that are very difficult to control in
future studies.
Future consideration in the research of photodynamic therapy in unresectable
cholangiocarcinoma is to increase the size of participants. Further investigation is
warranted in the combination of combination therapy of photodynamic therapy with
different chemotherapy and radiation. Future study to evaluate photodynamic therapy
and photodynamic therapy plus adjuvant therapy for unresectable cholangiocarcinoma is
required to substantiate the results in this review.
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